Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at zalutumumab for squamous cell carcinoma of the head and neck
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at zalutumumab for head and neck cancer that continued to grow or came back after chemotherapy with a
Many head and neck cancers are squamous cell carcinomas. Squamous cells are the flat, skin like cells that cover the inside of the mouth, nose and throat. Carcinoma just means cancer. So squamous cell carcinoma is cancer that starts in these cells.
In this trial, the researchers wanted to find out if zalutumumab stopped or slowed down the growth of squamous cell carcinoma. And to see if it could improve
- See if zalutumumab helped people with head and neck cancer
- Learn more about the side effects
Summary of results
The trial team found that zalutumumab increased the amount of time it took for squamous cell carcinoma of the head and neck to start growing again.
- 191 had zalutumumab and best supportive care
- 95 had best
Overall the average amount of time people lived was
- Just over 6½ months for those who had zalutumumab
- Just over 5 months for those who didn’t have zalutumumab
6 months after treatment, 57 out of every 100 people (57%) who had zalutumumab were still alive. 42 out of every 100 people (42%) who didn’t have zalutumumab were still alive.
The average length of time it took for the cancer to start growing again was
- Just under 10 weeks for those who had zalutumumab
- Just over 8 weeks for those who didn’t have zalutumumab
The most common side effects were
The trial team concluded that although zalutumumab didn’t increase the amount of time people lived, it did increase the amount of time it took for the cancer to start growing again.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Prof Christopher Nutting
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer